glp 1 agonist statpearls A Closer Look at the Dermatological Profile of GLP-1 Agonists Glucagon-like peptide-1 receptor agonists: a

Description

It's something like 27 more gallbladder-related events per every 10,000 patients treated per year, so it's a pretty small absolute risk. He added that the incidence of gallbladder events often increases after weight loss in general, but some studies suggest that GLP-1 drugs slow down gallbladder motility which could create a sludge that leads to gallstones (8)

[DOI] [PMC free article] [PubMed] [Google Scholar] 40.Akbari P., Gilani A., Sosina O., Kosmicki J.A., Khrimian L., Fang Y.Y., Persaud T., Garcia V., Sun D., Li A., et al

An alternative, more effective strategy might involve delaying patient enrollment initially, accumulating stock, and then expanding the patient pool in later periods

But were a long way from solving this problem

So far four studies for cardiovascular safety studies have been completed and published: The EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin vs